{
    "root": "2f09b4de-29f7-c302-3402-6303a8e2cc7d",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Azacitidine",
    "value": "20241030",
    "ingredients": [
        {
            "name": "Azacitidine",
            "code": "M801H13NRU",
            "drugbank_id": "https://go.drugbank.com/drugs/DB00928"
        },
        {
            "name": "mannitol",
            "code": "3OWL53L36A",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_29864"
        }
    ],
    "indications": {
        "text": "azacitidine injection nucleoside metabolic inhibitor indicated treatment : adult patients following fab myelodysplastic syndrome ( mds ) subtypes : refractory anemia ( rheumatoid arthritis ) refractory anemia ringed sideroblasts ( rars ) ( accompanied neutropenia thrombocytopenia requiring transfusions ) , refractory anemia excess blasts ( raeb ) , refractory anemia excess blasts transformation ( raeb-t ) , chronic myelomonocytic leukemia ( cmmol ) . ( 1.1 )",
        "doid_entities": [
            {
                "text": "myelodysplastic syndrome (DOID:0050908)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0050908"
            },
            {
                "text": "syndrome (DOID:225)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_225"
            },
            {
                "text": "mds (DOID:0060469)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0060469"
            },
            {
                "text": "anemia (DOID:2355)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_2355"
            },
            {
                "text": "rheumatoid arthritis (DOID:7148)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_7148"
            },
            {
                "text": "arthritis (DOID:848)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_848"
            },
            {
                "text": "neutropenia (DOID:1227)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1227"
            },
            {
                "text": "thrombocytopenia (DOID:1588)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1588"
            },
            {
                "text": "chronic myelomonocytic leukemia (DOID:0080188)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0080188"
            },
            {
                "text": "leukemia (DOID:1240)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1240"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "chronic myelomonocytic leukemia",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_98823"
            }
        ]
    },
    "contraindications": {
        "text": "substitute azacitidine injection oral azacitidine . dosing regimen azacitidine injection differ oral azacitidine ( 2.1 , 5.1 ) . mds : recommended starting first treatment cycle , patients regardless baseline hematology values , azacitidine injection75 mg/m 2 daily 7 days administered subcutaneous injection intravenous infusion . full prescribing information schedule subsequent cycles . premedicate nausea vomiting ( 2.2 ) . continue treatment long patient continues benefit ( 2.3 ) . monitor patients hematologic response renal toxicity ; delay reduce appropriate ( 2.3 , 2.6 , 2.7 ) .",
        "doid_entities": [
            {
                "text": "mds (DOID:0060469)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0060469"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "supplied azacitidine injection supplied lyophilized powder 100 mg single-dose vials packaged cartons 1 vial ( ndc 75907-225-11 ) . storage store unreconstituted vials 20\u00b0c 25\u00b0c ( 68\u00b0f 77\u00b0f ) ; ( usp controlled room temperature ) . handling disposal azacitidine injection hazardous . follow applicable special handling disposal procedures.1",
    "adverseReactions": "advanced malignant hepatic tumors ( 4.1 ) . hypersensitivity azacitidine mannitol ( 4 . 2 ) .",
    "indications_original": "Azacitidine for injection\u00a0is\u00a0a\u00a0nucleoside\u00a0metabolic\u00a0inhibitor\u00a0indicated\u00a0for\u00a0the\u00a0treatment of: Adult patients with the following FAB myelodysplastic syndrome\u00a0(MDS)\u00a0subtypes:\u00a0Refractory\u00a0anemia\u00a0(RA)\u00a0or\u00a0refractory\u00a0anemia\u00a0with\u00a0ringed sideroblasts (RARS) (if accompanied by neutropenia or\u00a0thrombocytopenia\u00a0or\u00a0requiring\u00a0transfusions),\u00a0refractory\u00a0anemia\u00a0with\u00a0excess blasts (RAEB), refractory anemia with excess blasts in\u00a0transformation (RAEB-T), and chronic myelomonocytic leukemia\u00a0(CMMoL). ( 1.1)",
    "contraindications_original": "Do not substitute azacitidine for injection for oral azacitidine. The indications and\u00a0dosing\u00a0regimen\u00a0for\u00a0azacitidine for injection\u00a0differ\u00a0from\u00a0that\u00a0of\u00a0oral\u00a0azacitidine\u00a0( 2.1 , 5.1 ). MDS:\u00a0The\u00a0recommended\u00a0starting\u00a0dosage\u00a0for\u00a0the\u00a0first\u00a0treatment\u00a0cycle,\u00a0for\u00a0all patients regardless of baseline hematology values, is Azacitidine for injection75 mg/m 2 daily for 7 days to be administered by subcutaneous injection\u00a0or\u00a0intravenous\u00a0infusion.\u00a0See\u00a0full\u00a0prescribing\u00a0information\u00a0for\u00a0schedule\u00a0for\u00a0subsequent cycles. Premedicate for nausea and vomiting ( 2.2 ). Continue\u00a0treatment\u00a0as\u00a0long\u00a0as\u00a0the\u00a0patient\u00a0continues\u00a0to\u00a0benefit( 2.3 ). Monitor\u00a0all\u00a0patients\u00a0for\u00a0hematologic\u00a0response\u00a0and\u00a0for\u00a0renal\u00a0toxicity;\u00a0delay or reduce dosage as appropriate ( 2.3 , 2.6 , 2.7 ).",
    "warningsAndPrecautions_original": "How Supplied \n                  \n                  Azacitidine for injection\u00a0is\u00a0supplied\u00a0as\u00a0a\u00a0lyophilized\u00a0powder\u00a0in\u00a0100\u00a0mg\u00a0single-dose vials packaged in cartons of 1 vial (NDC 75907-225-11). \n                  \n                     Storage \n                  \n                  Store unreconstituted vials at 20\u00b0C to 25\u00b0C (68\u00b0F to 77\u00b0F); (See USP Controlled Room Temperature). \n                  \n                     Handling\u00a0and\u00a0Disposal \n                  \n                  Azacitidine for injection\u00a0is\u00a0a\u00a0hazardous drug.\u00a0Follow\u00a0applicable special\u00a0handling\u00a0and\u00a0disposal\u00a0procedures.1",
    "adverseReactions_original": "Advanced Malignant Hepatic Tumors ( 4.1 ) . Hypersensitivity to Azacitidine or Mannitol (4 .2 ) .",
    "drug": [
        {
            "name": "Azacitidine",
            "drugbank_id": "https://go.drugbank.com/drugs/DB00928"
        }
    ]
}